Drug Type Biological products |
Synonyms Bovactant, Calf lung surfactant extract (CLSE), Calfactant (USAN) + [1] |
Target- |
Mechanism Cell membrane permeability enhancers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (01 Jul 1998), |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03317 | Calfactant |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Respiratory Distress Syndrome, Newborn | TR | - | 31 Oct 2018 |
Respiratory Distress Syndrome, Newborn | MY | - | 31 Oct 2018 |
Respiratory Distress Syndrome | US | 01 Jul 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bronchiolitis | Phase 2 | US | 12 Jan 2019 | |
Bronchiolitis | Phase 2 | US | 12 Jan 2019 | |
Acute Lung Injury | Preclinical | US | - | - |
Not Applicable | 30 | (Calfactant) | rktepmaafd(sypaxrpyxb) = glfcbuqutn cmkhapnfue (gofztoziji, ukzfnjmkkj - hyebjqtkqg) View more | - | 06 Jun 2017 | ||
(Poractant Alfa) | fqoscgkhvx(mpiqxubtmd) = zgeqnbakpb shwdwdelna (iyzbzsbybh, mslexolmyg - ayaoqfgvpw) View more | ||||||
Phase 3 | 85 | (Treatment Surfactant (Infasurf) ONY, NY) | qwdfixpjlg(ifpcnbazio) = rcydedrmcq wjzrjurjna (ylmwbniwbs, mvzbqjmsaw - glfvdelnmd) View more | - | 28 Jun 2016 | ||
Sham (Sham (no Treatment)) | qwdfixpjlg(ifpcnbazio) = dhrlvipipu wjzrjurjna (ylmwbniwbs, buiokxcqhh - pyjjnwonwr) View more |